194 related articles for article (PubMed ID: 38172843)
21. Effects of epidural anesthesia on the prognosis of ovarian cancer-a systematic review and meta-analysis.
Shen H; Pang Q; Gao Y; Liu H
BMC Anesthesiol; 2023 Nov; 23(1):390. PubMed ID: 38030996
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Ovarian Cancer: A Systematic Review and Meta-Analysis of Observational Studies.
Huang QT; Zhou L; Zeng WJ; Ma QQ; Wang W; Zhong M; Yu YH
Cell Physiol Biochem; 2017; 41(6):2411-2418. PubMed ID: 28467978
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological characteristics and prognostic value of the cancer stem cell marker ALDH1 in ovarian cancer: a meta-analysis.
Zhao W; Zang C; Zhang T; Li J; Liu R; Feng F; Lv Q; Zheng L; Tian J; Sun C
Onco Targets Ther; 2018; 11():1821-1831. PubMed ID: 29662319
[TBL] [Abstract][Full Text] [Related]
24. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.
Hu Q; Gou Y; Sun C; Ding W; Xu K; Gu B; Xia G; Ding Q
Urol Oncol; 2014 Jan; 32(1):50.e1-8. PubMed ID: 24239465
[TBL] [Abstract][Full Text] [Related]
26. Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis.
Jin Y; Ma X; Yang Z; Zhang N
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):697-705. PubMed ID: 36720459
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis.
Yu L; Deng L; Li J; Zhang Y; Hu L
Gynecol Oncol; 2013 Feb; 128(2):391-6. PubMed ID: 23142075
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
[TBL] [Abstract][Full Text] [Related]
29. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T
Front Immunol; 2022; 13():827788. PubMed ID: 35211122
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of C-reactive protein levels in patients with bone neoplasms: A meta-analysis.
Li W; Luo X; Liu Z; Chen Y; Li Z
PLoS One; 2018; 13(4):e0195769. PubMed ID: 29668751
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Significance of Survivin Expression in Patients with Ovarian Carcinoma: A Meta-Analysis.
Gąsowska-Bajger B; Gąsowska-Bodnar A; Knapp P; Bodnar L
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669912
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
33. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.
Hosono S; Kajiyama H; Mizuno K; Sakakibara K; Matsuzawa K; Takeda A; Kawai M; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2011 Oct; 16(5):524-32. PubMed ID: 21431342
[TBL] [Abstract][Full Text] [Related]
34. Prognostic and clinical implications of c-erbB-2 expression in patients with oral cancer: A meta-analysis.
Meng Y; Yang P; Ma L
Medicine (Baltimore); 2020 Jun; 99(23):e20575. PubMed ID: 32502026
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.
Guo C; Yan C; Qu L; Du R; Lin J
Arch Gynecol Obstet; 2021 Feb; 303(2):285-311. PubMed ID: 33222040
[TBL] [Abstract][Full Text] [Related]
36. Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.
Zhou M; Yu P; Qu X; Liu Y; Zhang J
PLoS One; 2013; 8(12):e81858. PubMed ID: 24324725
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of the lysyl oxidase family in ovarian cancer.
Ye M; Zhou J; Gao Y; Pan S; Zhu X
J Clin Lab Anal; 2020 Dec; 34(12):e23538. PubMed ID: 33058284
[TBL] [Abstract][Full Text] [Related]
38. The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis.
Gao N; Yang RN; Meng Z; Wang WH
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30352836
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of HE4 in patients with ovarian cancer.
Yuan C; Li R; Yan S; Kong B
Clin Chem Lab Med; 2018 Jun; 56(7):1026-1034. PubMed ID: 29420303
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis.
Zheng Z; Zhou L; Gao S; Yang Z; Yao J; Zheng S
Int J Med Sci; 2013; 10(6):653-64. PubMed ID: 23569429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
